What changed in Illumina, Inc.'s latest annual report
In the year ended 28 Dec 2025, Illumina, Inc.'s revenue fell 0.7% to USD 4.34bn, from USD 4.37bn; shareholders' equity rose 14.7% to USD 2.72bn, from USD 2.37bn; total assets rose 5.4% to USD 6.64bn, from USD 6.30bn.
Year ended 28 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 4.37bn to USD 4.34bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.37bn | 4.34bn | Down 0.7% |
| Net income | -1.22bn | 850.00m | Not comparable |
| Total assets | 6.30bn | 6.64bn | Up 5.4% |
| Shareholders' equity | 2.37bn | 2.72bn | Up 14.7% |
Questions people ask
Did Illumina, Inc.'s revenue grow last year?
Revenue fell 0.7%, from USD 4.37bn to USD 4.34bn in the year ended 28 Dec 2025.
Is Illumina, Inc. profitable?
Yes. Net income was USD 850.00m in the year ended 28 Dec 2025. The year before: a net loss of USD 1.22bn.
Where do these numbers come from?
From Illumina, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Illumina, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Agilent Technologies, Inc.Cash and cash equivalents up 34.6%
- Waters CorporationCash and cash equivalents up 80.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- Avantor, Inc.Cash and cash equivalents up 39.5%
- 10x Genomics, Inc.Total liabilities up 17.5%
- Bio-Rad Laboratories, Inc.Shareholders' equity up 13.5%